Cerevel Therapeutics Holdings Overview

Cerevel Therapeutics Holdings EBIT

EBIT (Earnings Before Interest and Taxes) analysis for CERE.

Quarterly EBIT

-$129.12M

↓ 28.01% YoY

As of Mar 31, 2024

Annual EBIT (TTM)

-$476.84M

↓ 20.17% YoY

Trailing 12 months ending Mar 31, 2024

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin